Use of the Thin Prep Pap Test in clinical practice

Area of Science:

• Gynecologic cytology
• Cervical cancer screening
• Medical device technology

Background:

• The Thin Prep Pap Test was FDA-approved in 1996 as an alternative to conventional smears.
• Cervical cancer screening relies on accurate cytological evaluation of Pap smears.
• Specimen adequacy and detection rates are critical metrics for evaluating screening methods.

Purpose of the Study:

• To assess the clinical utility of Thin Prep (TP) thin-layer technology for cervicovaginal screening.
• To compare specimen adequacy and lesion detection rates between TP and conventional smear (CS) methods.
• To evaluate the impact of TP on the atypical squamous cells of undetermined significance/squamous intraepithelial lesion (ASCUS SIL) ratio.

Main Methods:

• A direct-to-vial study evaluated 15,006 cervical smears over 10 months (May 1997-February 1998).
• Samples included 5,423 conventional smears (CS) and 9,583 Thin Prep slides (TP).
• Specimen adequacy and detection rates for cervical lesions (LSILs, HSILs) were compared between the two methods.

Main Results:

• The TP method significantly improved specimen adequacy, reducing "satisfactory but limited by" rates by 97% and unsatisfactory rates by 63%.
• TP slides showed a 267% increase in low-grade squamous intraepithelial lesion (LSIL) detection (3.6% vs. 0.98%).
• TP detected a threefold increase in high-grade squamous intraepithelial lesions (HSILs) (1.0% vs. 0.3%) and reduced the ASCUS SIL ratio by 54%.

Conclusions:

• The Thin Prep Pap Test significantly increases the detection of LSILs and HSILs compared to conventional smears.
• Thin Prep technology substantially improves specimen adequacy in routine cervicovaginal screening.
• The TP method offers a more effective alternative for cervical cancer screening in clinical practice.